In myeloid malignancies, FOXP1 was reported as a target of deletion in both AML[9] and in myeloproliferative neoplasms[10].We also report here for the first time that FOXP1 is deregulated in MDS/AML cases. This evidence concerns the gene FOXP1 and myeloproliferative disorder.